LRRK2 Kinase Inhibitors (Oncodesign/Servier)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameLRRK2 Kinase Inhibitors (Oncodesign/Servier)
Drug Alias NameLRRK2 Kinase Inhibitors (Oncodesign Biotechnology)Leucine-Rich Repeat Kinase 2 Inhibitors (Oncodesign Biotechnology)LRRK2 kinase inhibitors (Oncodesign Biotechnology)ODS-2005294
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLeucine-rich repeat serine/threonine-protein kinase 2 inhibitors
TargetsLeucine-rich repeat serine/threonine-protein kinase 2
Therapy Area/IndicationsParkinson DiseaseCentral Nervous System DiseasesNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesOncodesign Services
China Registration ClassN/A

Develop Information

Active CompaniesLaboratoires Servier
Inactive CompaniesOncodesign Services
Active IndicationsParkinson Disease
Inactive IndicationsCentral Nervous System DiseasesNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A